Skip to main content
SpringerLink
Log in

The Authors’ Reply

  • Correspondence
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Diamantopoulos A, Sawyer L, Ogale S, et al. Validity of cost and utility results? [letter]. Pharmacoeconomics 2012; 30 (10): 977.

    Article  PubMed  Google Scholar 

  2. Nguyen CM, Bounthavong M, Mendes MAS, et al. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. Pharmacoeconomics 2012; 30 (7): 575–93.

    Article  PubMed  Google Scholar 

  3. Rawles J. Castigating QALYs. J Med Ethics 1989; 15: 143–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Lan JL, Chou SJ, Chen DY, et al. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc 2004 Aug; 103 (8): 618–23.

    CAS  PubMed  Google Scholar 

  5. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004 Feb 28; 363 (9410): 675–81.

    Article  CAS  PubMed  Google Scholar 

  6. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan; 340 (4): 253–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

MB has been awarded a grant from UCB Pharmaceuticals to evaluate certolizumab (CIMZIA®) at the Veterans Affairs San Diego Healthcare System that was pending during the writing of the study manuscript.[2] All remaining authors declare that no conflicts of interest exist. In addition, the study was not funded.

Author information

Authors and Affiliations

  1. Veterans Affairs San Diego Healthcare System, San Diego, California, USA

    Mark Bounthavong, Christine M. Nguyen, Margaret A. S. Mendes, Melissa L. D. Christopher, Josephine N. Tran, Rashid Kazerooni & Anthony P. Morreale

Authors
  1. Mark Bounthavong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christine M. Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Margaret A. S. Mendes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Melissa L. D. Christopher
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Josephine N. Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rashid Kazerooni
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anthony P. Morreale
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bounthavong, M., Nguyen, C.M., Mendes, M.A.S. et al. The Authors’ Reply. PharmacoEconomics 30, 977–978 (2012). https://doi.org/10.2165/11633710-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11633710-000000000-00000

Keywords

Search

Navigation